In simple words: This code is used for a special Medicare project to track the status of patients with early-stage non-small cell lung cancer who have not yet received treatment to shrink the tumor and have no signs of the cancer spreading.

This code is used to report a patient's current disease status for a Medicare-approved demonstration project when the patient has Stage I non-small cell lung cancer before receiving neoadjuvant therapy, and there is no evidence of disease progression, recurrence, or metastases. It's specifically for patients with non-small cell lung cancer whose extent of disease is initially established as Stage I, before any neoadjuvant therapy (if any), and with no evidence of disease progression, recurrence, or metastases.

Example 1: A patient diagnosed with Stage I non-small cell lung cancer is enrolled in a Medicare-approved demonstration project before starting neoadjuvant chemotherapy. The physician reports G9063 to document the patient's disease status., A patient with Stage I non-small cell lung cancer is being evaluated for surgery. Prior to any neoadjuvant therapy, the oncologist reports G9063 as part of the Medicare demonstration project data collection., A patient diagnosed with Stage IA non-small cell lung cancer and no evidence of metastasis is enrolled in the Medicare demonstration project. Before starting radiation therapy, the physician uses G9063 to report the patient's disease stage and lack of progression.

Documentation should include confirmation of the patient's non-small cell lung cancer diagnosis, staging information indicating Stage I disease, and the absence of disease progression, recurrence, or metastases. The patient's participation in the Medicare demonstration project must also be documented.

** This code is part of a Medicare demonstration project to assess treatment patterns and outcomes for lung cancer. It helps track and analyze data related to different stages and treatment approaches for this specific type of cancer.